The gut microbiota is a key area for personalised nutrition, but its application requires robust methods, carefully selected biomarkers and cautious interpretation. The article examines the complementary roles of qPCR and NGS, as well as the B2B/OEM potential of Helyx Industries S.p.A. in the nutraceutical sector.

qPCR remains a key technology in molecular diagnostics, but challenges such as signal drift, reagent stability, quality control and throughput limitations continue to hinder its widespread adoption. This article examines the most significant solutions currently available, integrated platforms, ambient-stable reagents, cloud computing and AI, with a focus on Helyx Industries’ Hyris platform.

Decentralised multiplex diagnostics can improve cost-effectiveness in hospitals not because the cost per test is lower, but because it reduces the costs associated with waiting: isolation, hospital stays, delays in decision-making and the overload on the central laboratory.

Decentralised molecular diagnostics brings testing closer to the point of care, reducing turnaround times and enabling more timely clinical decisions. This article examines the operational and clinical benefits of point-of-care models, focusing on distributed workflows, quality, operational continuity and integration between peripheral sites and the central laboratory.